Abstract 1494P
Background
Patients (pts) with metastatic NSCLC often present ECOG-PS 2+ at diagnosis. Identifying those pts with a life expectancy ≤ 90 d allows for early referral to palliative care and favors better adequacy of resources. This study aimed to characterize those factors associated with an overall survival (OS) < 90 d. (ClinicalTrials.gov: NCT04306094).
Methods
It is a prospective cohort study (Nov/17 – Jun/23). All eligible pts met the following criteria: ≥ 18 y.o.; treatment-naive, histologically proven NSCLC stages IVA-IVB; ECOG-PS 2-4; no other cancer, and were consecutively included after signing informed consent. We collected 83 baseline features, including, but not restricted to, demographics, histology, EGFR-mutational status, medical history, nutritional status and body composition, smoking status, symptom burden, palliative scores, and laboratory values. We defined cachexia as published by Fearon et al. (2011). Logistic regression (LR) was performed to adjust prognostic factors related to OS < 90 d. The Hosmer-Lemeshow test was conducted to assess the goodness of fit of the LR model.
Results
180 pts were included: median age was 67 y.o. (18-86), 58% were male, and 152 pts (84%) were current/previous smokers. In terms of ECOG-PS, 107 presented PS2 (59%), 57 PS3 (32%), and 16 PS4 (9%). Adenocarcinoma was the most common histology (61%, EGFR mut in 16 pts), followed by squamous histology (26%). CNS metastases were detected in 40 pts (22%) and liver involvement in 17 pts (9%). Median OS was 87 d, and 91 pts (51%) had OS < 90 d. According to ECOG-PS, mOS was 106 d (PS2), 55 d (PS3) and 24 d (PS4) (p
Conclusions
In this cohort of pts, Hb level, PAP score, use of supplemental O2, presence of cachexia and ECOG-PS 3-4 were important determinants of OS < 90 d. Prognostic models incorporating these factors should be developed to improve OS estimation in these pts.
Clinical trial identification
NCT04306094.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. De Castro Jr.: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, TEVA, Lilly; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Libbs, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, TEVA, Yuhan, Sanofi; Financial Interests, Local PI: Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Roche; Financial Interests, Steering Committee Member: AstraZeneca, Bayer, Beigene, Merck Sharp & Dohme; Financial Interests, Personal, Steering Committee Member: GSK, Novartis; Financial Interests, Institutional, Local PI: Lilly, Pfizer, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10